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A meeting of 29 senior scientists from Europe, the USA, India
and Australia, was held in Naarden, The Netherlands on November
14–16, 2008, to establish consensus Best Practice Guidelines for
molecular diagnosis of Duchenne and Becker muscular dystrophy
(DMD/BMD). New therapeutic trials for DMD demand accurate
diagnosis of the disorder, especially where the therapy is targeted
towards speciﬁc mutations. These guidelines aim to help diagnos-
tic laboratories attain that accuracy by describing the minimum
standards for acceptable molecular diagnostic testing of DMD.
For the different types of clinical referral received by a molecular
diagnostic laboratory, the guidelines recommend the appropriate
tests to be carried out, interpretation of the results and how those
results should be reported.2. Internal and external quality control
All laboratories offering molecular genetic testing for DMD/
BMD must follow established good laboratory practice, as docu-
mented for example in Guidelines for Quality Assurance in Molecular
Genetic Testing, published by the Organisation for Economic
Co-operation and Development [1].
In addition to following such guidelines, a laboratory should
ideally demonstrate that it complies with internationally recogni-
sed standards for laboratory testing (e.g. ISO standards 15189:
2007 Medical laboratories – Particular requirements for quality and
competence), by achieving formal accreditation with a member
organisation of the International Laboratory Accreditation Cooper-
ation (ILAC) or equivalent national accreditation body.
All tests should be validated/veriﬁed in individual laboratories
prior to implementation; it is not acceptable to rely on the valida-
tion of a test by another laboratory, since that does not guarantee0960-8966/$ - see front matter  2010 Elsevier B.V. All rights reserved.
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control samples representing all mutation types should therefore
be collected by each laboratory to facilitate test validation/veriﬁca-
tion, and exchange of samples between laboratories is encouraged
to allow this. External quality assessment schemes provide further
validation of testing procedures and methods, and laboratories
should participate in appropriate EQA schemes for DMD testing.
If this is not possible, inter-laboratory exchange of samples should
be arranged to compare and validate test results.
3. Types of laboratory referral
Patient samples are referred to clinical molecular genetic labo-
ratories for the following investigations:
3.1. Diagnosis in male patients
Affected males suspected to have a dystrophinopathy based on
high serum creatine kinase (CK) levels and/or muscle biopsy, are
referred for a molecular conﬁrmation of the clinical diagnosis
(see Fig. 1). Molecular conﬁrmation of a dystrophinopathy is
achieved by demonstrating the presence of a clearly pathogenic
variant in the DMD gene. Absence of a DMDmutation would reduce
the likelihood of a patient having a dystrophinopathy, with the
reduction being dependent on the sensitivity of the mutation
screening procedure(s) used. It is currently not possible to refute
a diagnosis of a dystrophinopathy based on the results of genetic
testing, since no mutation detection protocol which is currently
available can demonstrate 100% sensitivity.
From the patients’ and relatives’ perspectives, the speed with
which a diagnosis can be made is extremely important in order
to minimize anxiety and to reduce the risk of recurrence of the dis-
ease in the family. Therefore, in some instances a muscle biopsy
and dystrophin analysis by immunohistochemistry might be
needed to establish a quick and deﬁnite diagnosis.
Appropriate genetic counselling in the family is dependent on
the knowledge of the diagnosis in the patient. This should be
borne in mind when determining the appropriate procedures
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Fig. 1. Flow chart for the diagnostic work-up of a dystrophinopathy.
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centres depending on the availability of different tests and facili-
ties, and economic factors.
3.1.1. Testing for deletions and duplications
Since whole exon deletions are the predominant type of muta-
tion in the DMD gene (65%), an initial screen which detects the
majority of deletions should be the minimum level of diagnostic
test offered. A number of methods have been described, with the
following being the most popular choices currently in use:
Multiplex PCR, to amplify the exons known to be most com-
monly deleted. The two PCR multiplex sets of Chamberlain et al.
[2] and Beggs et al. [3], or recent improvements on these made
by a number of centres, collectively enable the detection of about
98% of all DMD deletions. These two assays do not characterise
the end points of all deletions, since they do not test all exons.
Where the end point(s) of a deletion is (are) not determined by
the multiplex PCR system being used, it is beneﬁcial to use addi-
tional PCR assays to characterise the extent of the deletion, when-
ever possible. Details of PCR primers for all DMD exons can be
found at www.dmd.nl
Quantitative assays of all exons offer an improvement in muta-
tion detection rate, since they will detect all whole exon deletions,
and additionally whole exon duplications (10% of DMD muta-
tions). Further advantages are that these assays characterise the
end points of most rearrangements (at the exon level of resolu-
tion), and can also be used for carrier testing of females. Of the
quantitative methods available, multiplex ligation-dependentprobe ampliﬁcation (MLPA) [4] is currently the most widely used
method among the workshop participants. Quantitative multiplex
PCR of selected exons (e.g. [5]) and Southern blot hybridisation
using cDNA probes [6] have both been widely used in the past,
but have been superseded in many labs by the convenience and
commercial availability of MLPA.
A recently developed quantitative approach to assay the DMD
gene with high resolution is array CGH (comparative genomic
hybridisation) (e.g. [7–9]). This method uses thousands of oligonu-
cleotides to interrogate copy number across the entire 2.2 MB
genomic region of the DMD gene including all exons and introns,
and thereby maps rearrangement breakpoints to relatively narrow
intervals depending on the spacing of the oligonucleotides at the
breakpoints. It also can detect loss or gain of sequences at intronic
breakpoints associated with some inversions and complex rear-
rangements, thereby offering a slightly higher mutation detection
rate than MLPA and other exon-based tests.
If a method identiﬁes an apparent single exon deletion or dupli-
cation based on the absence or increased ampliﬁcation, respec-
tively, of a single PCR ampliﬁcation, or hybridisation, that result
must be conﬁrmed using an alternative assay. This different assay
will verify whether the initial result could have been caused by a
sequence variant (e.g. SNP), preventing hybridisation of a primer,
probe, etc., or for duplications if the result was an anomaly. This
can be achieved using the same method, for example with different
primers to amplify an exon which looks deleted with multiplex
PCR, or using a different method to assay that exon. High density
array CGH has a further advantage here over most other methods
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or duplications are likely to be detected by several oligonucleotides
on the array. This eliminates the possibility of a false positive result
due to the presence of a SNP in a single probe or primer.
If a duplication of a single or multiple exons is identiﬁed it is
important to test all exons for the possibility of additional exons
being duplicated, since a number of apparently non-continuous
duplications have been reported [9,10].
When interpreting the deletion or duplication result (see be-
low) if the predicted severity is discrepant with the observed clin-
ical phenotype, it may be useful to repeat the tests on a second
sample and/or to carry out additional laboratory tests using differ-
ent methods, or offering more detail, in order to look for an expla-
nation to the discrepancy. This additional work is not essential, and
may not be possible in all centres.
3.1.2. Testing for other mutation types
If no deletion or duplication has been found, the clinical diagno-
sis cannot be conﬁrmed nor excluded. If the clinical features,
family history, and/or results of muscle biopsy suggest a dystro-
phinopathy, further tests should be offered to search for a patho-
genic mutation. It is not expected that full mutation screening is
available in every laboratory, but laboratories in which it is not
available should seek an arrangement with another lab to carry
out these further tests.
Numerous methods have been applied to scan the DMD gene for
nucleotide changes, including: SSCP [11], dHPLC [12], FM-CSCE
[13], PTT [14], HRM [15]. These pre-screens aim to offer a lower cost
alternative to sequencing all the 79 DMD exons, however, since the
cost of sequencing has reduced dramatically over recent years it
may be more appropriate to sequence the full gene now [16].
Sequencing can be performed on RT-PCR derived cDNA from
muscle RNA, or on genomic DNA. If a pathogenic variant is identi-
ﬁed in cDNA, it should be followed by sequencing of the appropri-
ate region(s) in genomic DNA to conﬁrm the result, and
characterise the variant at the nucleotide level to allow future
DNA-based testing in relatives. Note that for some variants identi-
ﬁed in cDNA it may not be straightforward or even possible to
characterise the sequence change at the genomic level, e.g. deep
intronic mutations.
Complex rearrangements, or variants located deep into the
large introns of the gene will not be detected using standard meth-
ods of DNA-based mutation screening, and RNA-based methods of-
fer a reasonable likelihood of being able to detect them. These
mutations appear to be of low frequency (approximately 2% of
DMD mutations).
Next generation sequencing approaches also offer improved
likelihood of being able to detect the full spectrum of DMD muta-
tions, since the whole gene can be sequenced, including the in-
trons. However, additional RNA-based studies may be required to
evaluate the pathogenic effects of some of the many intronic vari-
ants likely to be detected.
In rare instances, the occurrence of more than one DMD muta-
tion in a family has been reported (e.g. [17]). So, in extended ped-
igrees with more than one affected male, it may be wise to test all
patients.
3.2. Carrier diagnosis for a known familial mutation
Carrier diagnosis of female relatives at risk of being heterozy-
gotes for a knownmutation can be conducted by most of the meth-
ods that have been used to identify the mutation in the index case
of the family. Whenever possible, a sample from the index case (or
a known carrier) should be run as a control sample or (at least) a
written report on the mutation of the index patient should be
available in order to avoid data transmission problems. Clearly,the method chosen to test female relatives must be capable of
detecting the mutation in the heterozygous state, i.e. masked by
the presence of the corresponding normal allele. Deletions there-
fore require either a quantitative method (such as MLPA or array
CGH), or a qualitative method, such as pulsed ﬁeld or ﬁeld inver-
sion gel electrophoresis [18].
If the mutation of the index case cannot be found in genomic
DNA from his mother, the frequency of germinal mosaics still con-
fers a signiﬁcant recurrence risk for future children (see below).
3.3. Carrier detection for an unknown mutation
If an affected male is not available to be tested, female relatives
at risk of being carriers should be offered mutation testing, using
any of the methods discussed above which are able to detect het-
erozygous mutations. Testing should start with the woman who
has the highest prior carrier risk, usually the mother of an index
case. An initial screen for deletions and duplications is a sensible
ﬁrst test, as in testing affected males. All the precautions associated
with testing amale for deletions and duplications are equally appli-
cable to testing females, such as the need to verify copy number
changes involving only a single exon. If no mutation is found and
before proceeding to more complex tests, it is recommended to re-
view the available clinical information. With a strong clinical diag-
nosis and/or X-linkage, sequencing or other point mutation
screening methods would be the ideal next step, but these may
not be available in all laboratories. If these are not available in a lab-
oratory, it is recommended that samples are forwarded to another
laboratory which is able to conduct these tests. Haplotype analysis
is an alternative (see below) if key family members are available.
3.4. Diagnosis of manifesting carriers
A small proportion of female carriers of DMD mutations exhibit
clinical symptoms, some of which can be as severe as found in
male patients. Norman and Harper [19] concluded that 2.5% of het-
erozygotes have muscle symptoms but the incidence of cardiomy-
opathy in female carriers may be higher [20,21]. Up to two thirds of
carriers have persistently elevated serum CK levels [22]. Conﬁrma-
tion of diagnosis for these manifesting females follows the same
principles as for affected males, and mutation screening follows
the same principles as testing for carrier status of an unknown
mutation. Clinical manifestation in females is believed to result
from non-random X-inactivation. However, a few manifesting fe-
males have been identiﬁed with two mutations (A.F. and C.R.M.
personal communication).
Chromosomal aberrations (45, X0; X-autosome translocations)
should also be considered in fully manifesting girls.
3.5. Prenatal diagnosis
Prenatal diagnosis for DMD/BMD should only be carried out for
male pregnancies. At present, it is not possible to predict whether a
female heterozygote for a DMDmutation will manifest any signs of
the disorder or not, and therefore it would be inappropriate to offer
prenatal diagnosis for a female fetus.
The familial mutation will preferably be known in advance of
testing a male pregnancy, and should be conﬁrmed before the pre-
natal test, or can be conﬁrmed in parallel with testing the fetus by
using the proband’s DNA as a control. The same technique can be
used to test for the mutation as was used to identify or verify the
mutation in the proband. A check for maternal cell contamination
(MCC) of the fetal DNA must be carried out, since its presence at a
signiﬁcant level may affect the interpretation of the fetal result.
This would be a particular problem for example when testing a
male fetus for a deletion using a non-quantitative PCR-based assay,
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a deletion in an affected male fetus, resulting in a false negative
diagnosis. A check for MCC can be done with markers from the dys-
trophin gene region (see Appendix) or with any polymorphic mar-
ker set used routinely in the laboratory, e.g. for identity testing.
Further details and recommendations for checking for maternal
cell contamination in prenatal samples can be found in the CMGS
Best Practice Guidelines [23].
3.6. Preimplantation genetic diagnosis (PGD)
PGD is a specialist test carried out in a limited number of cen-
tres. For PGD, the same analytical considerations apply as for pre-
natal testing, but the special requirements of a PGD setting need to
be considered, as documented in the Best Practice Guidelines from
the European Society of Human Reproduction and Embryology
PGD Consortium [24]. These tests will not be discussed further in
this document.
3.7. Haplotype analysis
Haplotype analysis to trace the inheritance of high and low risk
DMD haplotypes within a family is an option for carrier detection
and prenatal diagnosis which may be available in some laborato-
ries. This method may be useful only if the family structure is suit-
able and the polymorphic markers used are informative. The
results should be interpreted with care, particularly if the diagnosis
is in any doubt.
At least three informative markers should be used, which
should include a minimum of one intragenic marker and extragen-
ic markers ﬂanking the dystrophin gene on either side.4. Result interpretation
4.1. Deletions and duplications
Whole exon deletions or duplications in the vast majority of
cases can be considered to be pathogenic. The severity of clinical
symptoms associated with these mutations does vary according
to which exons are affected and the number of exons affected, but
the principle factor which determines the severity is the effect that
the mutation has on the reading frame. Deletions which disrupt the
translational reading frame generally cause a severe (Duchenne)
phenotype, whereas those which leave the reading frame intact
have a less severe affect and result in the milder Becker phenotype.
This reading frame hypothesis is consistent in about 92% of cases
[25]. It should be used as a statistical basis for disease course pre-
diction, but care should be taken when used for individual disease
course prediction. The reading frame prediction is generally appli-
cable to duplications, but should be used more cautiously because
most techniques do not allow the determination of whether a
duplication is arranged in a head-to-tail orientation. Additional
tests may be carried out to evaluate the orientation of duplicated
material, but such tests are not required for routine diagnosis. It
may be important to determine this level of detail associated with
duplication mutations if exon skipping therapy is to be carried out.
A reading frame checker is available at www.dmd.nl
4.2. Other mutations
With present knowledge, mutations leading to the generation of
a premature stop codon are considered incompatible with full-
length protein synthesis and causative of a dystrophinopathy.
However, a number of exceptions are on record in the DMD gene
of exon skipping associated with nonsense-mutations (e.g. [26]).Likewise, at the extreme 30 end of the gene, nonsense-mutations
may lead to a milder phenotype than expected.
Mutations within splice consensus sequences will almost
invariably lead to aberrant splicing and should be checked for their
effect on exon skipping and maintenance of the reading frame in
the mRNA. Mutations in the immediate vicinity of splice consensus
sites should be investigated by splice prediction programmes for
their effect on splicing probability. If possible, muscle mRNA anal-
ysis should be performed or recommended.
Mutations leading to amino acid substitutions should be
checked for their effect on protein structure and function by suit-
able algorithms (e.g. SIFT, Polyphen). With a huge, still not fully
characterised protein like dystrophin, the limited power of such
predictions should be recognised.
All sequence variants should be checked against the SNP dat-
abases (dbSNP) and the DMD gene mutation databases
(www.dmd.nl; www.umd.be/DMD/W_DMD/index.html). For fur-
ther recommendations about interpretation and reporting of
unclassiﬁed sequence variants, see the Best Practice Guidelines
published by CMGS and VKGL [27].
If a DMDmutation has not been identiﬁed in a patient suspected
of having a dystrophinopathy, alternative diagnoses should perhaps
be considered, depending on the available clinical evidence and test
results. Possible alternatives, especially for patients with milder
clinical severities (referredwith BMD), but also for patients referred
withDMD at an early age,might include a limb girdlemuscular dys-
trophy, or Emery Dreifuss muscular dystrophy. If, however, the
diagnosis of DMD/BMD has been established by immunohisto-
chemistry and/or immunoblotting, a second blood sample should
be requested and analysed in order to rule out a sample swap.4.3. Haplotype analysis
Haplotype analysis is often applied for families in which the
causative mutation has not been identiﬁed. Individual haplotypes
should be constructed from the observed marker alleles, and dis-
played in a pedigree drawing. Carrier and prenatal risks should
be calculated, based on the segregation of the high and low risk
haplotypes, using Bayesian methods [28]. The genetic distances
of intragenic and ﬂanking markers can be found at the DMD web-
site (www.dmd.nl). In cases where a recombination is observed the
calculations become more complex and may need to consider the
likely location of an unknown mutation, based on the site of the
recombination and relative likelihood of an unknown mutation
residing on each side of the recombination. However, considerable
caution must be taken with using linkage data for clinical determi-
nation of risks; it assumes the locus responsible for the disorder in
a family is known (i.e. the DMD gene). Therefore the clinical diag-
nosis must be clearly deﬁned as a dystrophinopathy, ideally by
muscle biopsy analysis, but care should be taken in relying on link-
age data to ascertain risks, especially in the absence of knowing the
pathogenic mutation in a family. At least in case of a recombina-
tion, the risk of the proband should be calculated by suitable soft-
ware (e.g. LINKAGE) or Bayesian logic.
With an established clinical diagnosis but in the absence of an
identiﬁed DMDmutation, serum CK values of women at carrier risk
are useful complementary information, making the risk calcula-
tions even more demanding, however.5. Result reporting
5.1. General points
When writing the report, it should be borne in mind that the re-
port may not be conﬁned to the addressee but could be copied and
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Therefore, it should contain all necessary information to be com-
prehensible on its own.
The reason for referral should be re-stated, which at least spec-
iﬁes the type of test that was requested, e.g. diagnostic, carrier, or
prenatal test. Reference to the laboratory tests carried out must in-
clude brief mention of the method(s) used and details of what was
tested, e.g. which exons were screened. If a commercial kit is used
(e.g. MLPA), the kit reference number(s) and version(s) should be
documented.
For the sake of subsequent analyses to be performed in the fam-
ily and for entry into patient registries it is recommended to use
standard nomenclature for the reporting of mutations. For whole
exon deletions and duplications, it is preferable to state in words
which exons are deleted/duplicated, e.g. ‘‘deletion of exons 3–7”,
rather than use HGVS nomenclature. The HGVS nomenclature
(www.hgvs.org) does not add any further information for these
mutations, unless the breakpoints of the mutation have been char-
acterised or at least narrowed down to a relatively small interval,
in which case it would be appropriate to quote the mutation using
full HGVS nomenclature. The report must clearly convey whether
the end points of a deletion or duplication have been determined,
so for example, the statement that a patient ‘‘has a deletion of
exons 3–7” conveys that the end points are deﬁned and exons 2
and 8 were present. If in this example exons 2 and 8 were not
tested, the report should state that the patient ‘‘has a deletion
which includes at least exons 3–7” and an additional statement
that ‘‘the end points of the deletion have not been determined”.
The predicted effect of deletions on the reading frame should also
be stated, clearly stating that it is a prediction. This can also be sta-
ted for duplications, but with greater caution since an assumption
is generally made about the location and orientation of the dupli-
cated sequence, as discussed above. If the deletion or duplication
has been characterised in cDNA, the effect on the RNA can of course
be given as a test result rather than a prediction.
For point mutations, HGVS recommended mutation nomencla-
ture must be used, stating the sequence change at the DNA level
(assuming it has been characterised in DNA), and (as predicted)
in the protein. Also for clarity it is useful to state in words what
the change is, and its predicted effect.
In all mutation reports, it is essential to quote the accession
number of the DMD reference sequence which has been used in
classifying the mutation (e.g. NM_004006.2).5.2. Speciﬁc points to include in reports
5.2.1. Diagnostic tests
5.2.1.1. Presence of mutation. Include details of the mutation (as
discussed in Section 5.1).
State that the presence of the mutation conﬁrms, or is consis-
tent with, the diagnosis. If the patient’s clinical phenotype (of
either DMD or BMD) is consistent with the predicted severity of
the mutation, the report can state speciﬁcally that the result con-
ﬁrms, or is consistent with, either DMD or BMD, or a female carrier
of DMD or BMD. If the genotype – phenotype is discordant, or if the
severity of the clinical phenotype is not speciﬁed in the referral, the
report can refer to a dystrophinopathy, rather than speciﬁcally
DMD or BMD.
Depending on local practice, it may be appropriate to offer car-
rier and prenatal tests to appropriate female relatives, and/or sug-
gest referral for genetic counselling. Also, it may be useful in a
separate document to the diagnostic report to inform patients
about the possibility of entering their mutation on a national
DMD Registry (e.g. www.dmdregistry.org) if they wish to be con-
sidered for therapeutic trials at any point in the future.5.2.1.2. Absence of mutation. The report should state that the result
neither conﬁrms nor excludes the diagnosis, but it may be appro-
priate to state that the diagnosis of DMD, BMD, or a dystrophinop-
athy, is less likely. The sensitivity of the tests must be given, with
references if appropriate. Further tests, if available, should be of-
fered such as sequencing, immunohistochemical analysis, or test-
ing of other genes, or if not available referral to another centre
should be offered. Haplotype analysis may be offered if required
for carrier or prenatal testing, if the family history or muscle biopsy
tests suggest a dystrophinopathy, and if the family structure is
suitable.
If an observed sequence variant cannot be classiﬁed according
to disease causality, the report should clearly state this and also
indicate that this result does not provide a basis for carrier testing
and prenatal diagnosis in the family.
5.2.2. Carrier tests
5.2.2.1. Presence of mutation. The report should state that the pres-
ence of a mutation conﬁrms the individual is a carrier of DMD,
BMD, or a dystrophinopathy (as appropriate, see discussion above).
Again, according to local practice, prenatal diagnosis might be of-
fered, and carrier testing and genetic counselling may be offered
to other appropriate relatives.
5.2.2.2. Absence of mutation. When the familial mutation is not
present in a carrier test the report should clearly state that the fe-
male tested is not a carrier of the familial mutation. The exception
to this would be if the individual is the mother of an affected boy(s)
with no previous family history of the disorder (sporadic cases). In
this case, the report must discuss the possibility that the mother
may be mosaic for the mutation, and offer prenatal diagnosis if
appropriate. The recurrence risk for offspring from the possibility
of being mosaic should be stated, quoting recent published data
which estimates a risk of about 9% associated with the high risk
haplotype [29].
If a female has no recurrence risk associated with the familial
mutation, it may be appropriate, depending on the nature of the
referral, to state that prenatal diagnosis or further carrier testing
of daughters are not indicated.
When the familial mutation is not known, and a mutation
screen has failed to identify a mutation in a potential carrier, the
carrier risk will be reduced depending on the detection rate of
the molecular tests performed. This reduction should be calculated
using Bayesian methods, and quoted on the report.
5.2.3. Prenatal tests
5.2.3.1. Presence of mutation. The implications of the presence of a
mutation in a prenatal diagnosis must be reported clearly, stating
that the (male) pregnancy is predicted to be affected with DMD,
BMD, or a dystrophinopathy (as appropriate). The report should
state that a signiﬁcant level of maternal cell contamination has
been excluded. If the mother does not carry the mutation somati-
cally, this result may show that she is a germline mosaic for the
mutation. This should be documented in the report, additionally
stating that the recurrence risk in future pregnancies is increased
accordingly.
5.2.3.2. Absence of mutation. Absence of the familial mutation in a
prenatal diagnosis, requires the report to state that the (male)
pregnancy is predicted to be unaffected by DMD, BMD, or dystro-
phinopathy (as appropriate) caused by the familial mutation. If
the mother is a full carrier of the mutation, this prenatal result will
itself exclude maternal cell contamination of the fetal DNA, and no
additional tests for MCC will be required. The report should still
state that a signiﬁcant level of MCC has been excluded.
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Appendix A
URLs of databases and resources:
dbSNP: http://www.ncbi.nlm.nih.gov/projects/SNP/
Human Genome Variation Society (for mutation nomenclature
recommendations): www.hgvs.org
Leiden DMD database: www.dmd.nl
French Universal Mutation Database DMD: www.umd.be/DMD/
W_DMD/index.html
Polyphen: http://genetics.bwh.harvard.edu/pph/
SIFT: http://sift.jcvi.org/
List of polymorphic markers: www.dmd.nl
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